Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Glomerulonephritis D005921 35 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Burns D002056 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Uremia D014511 33 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Michibayashi T Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways. 2005 J. Atheroscler. Thromb. pmid:16020916
Svenstrup Poulsen T et al. A critical appraisal of the phenomenon of aspirin resistance. 2005 Cardiology pmid:16020925
Walsh DS et al. Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. 2005 J. Surg. Res. pmid:16045935
Rodrigue ME et al. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. 2005 Can. J. Physiol. Pharmacol. pmid:16049546
Esser R et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. 2005 Br. J. Pharmacol. pmid:15655513
Sullivan JC et al. Sexual dimorphism in renal production of prostanoids in spontaneously hypertensive rats. 2005 Hypertension pmid:15699443
Chan CP et al. Inhibition of cyclooxygenase activity, platelet aggregation and thromboxane B2 production by two environmental toxicants: m- and o-cresol. 2005 Toxicology pmid:15664436
Massicot F et al. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. 2005 Basic Clin. Pharmacol. Toxicol. pmid:15667592
Lee GY et al. Antiplatelet activity of BRX-018, (6aS,cis)-malonic acid 3-acetoxy-6a9-bis-(2-methoxycarbonyl-acetoxy)-6,6a,7,11b-tetrahydro-indeno[2,1-c]chromen-10-yl ester methylester. 2005 Thromb. Res. pmid:15668191
Gama de Abreu M et al. Vaporized perfluorohexane attenuates ventilator-induced lung injury in isolated, perfused rabbit lungs. 2005 Anesthesiology pmid:15731599
Ye T et al. [Insulin resistance and effects of intravenous acute saline load on renal production of prostaglandin I2 and thromboxane A2 in salt-sensitive hypertensive patients]. 2005 Di Yi Jun Yi Da Xue Xue Bao pmid:15684012
Al Kadi H et al. A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight. 2005 Hum. Reprod. pmid:16006463
Beretta C et al. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. 2005 Pharmacol. Res. pmid:15939622
Klein Gunnewiek JM et al. The influence of acetylsalicylic acid intake by healthy volunteers on duplicate PFA-100 measurements. 2005 Blood Coagul. Fibrinolysis pmid:15970717
Jin YR et al. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization. 2005 J. Pharmacol. Exp. Ther. pmid:15328379
Persico N et al. Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. 2005 Ultrasound Obstet Gynecol pmid:16184506
Perini JA et al. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. 2005 Clin. Pharmacol. Ther. pmid:16198655
Maree AO et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. 2005 J. Am. Coll. Cardiol. pmid:16198840
Kataoka M et al. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. 2005 Am. J. Respir. Crit. Care Med. pmid:16192456
Munsterhjelm E et al. Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. 2005 Anesthesiology pmid:16192763
Hsiao G et al. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. 2005 J. Lab. Clin. Med. pmid:16194683
Xiaorong C et al. Effects of medicinal cake-separated moxibustion on plasma 6-keto-PGF1alpha and TXB2 contents in the rabbit of hyperlipemia. 2005 J Tradit Chin Med pmid:16136949
Oliveira RL et al. Postmenopausal hormone replacement therapy increases plasmatic thromboxane beta 2. 2005 Int. J. Cardiol. pmid:15771927
Cryer B et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. 2005 Clin Ther pmid:15811481
Watanabe H et al. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. 2005 Circ. J. pmid:15635218
Maruyama T et al. Thromboxane-dependent portopulmonary hypertension. 2005 Am. J. Med. pmid:15639216
Falco A et al. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. 2005 Atherosclerosis pmid:16285996
Noguchi M et al. Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites. 2005 Biol. Pharm. Bull. pmid:16272692
Ando K [Synthesis of 2-, 4- and 5-(2-alkylcarbamoyl-1-methylvinyl)-7-alkyloxybenzo[b]furans and their leukotriene B4 receptor antagonistic activity]. 2005 Yakugaku Zasshi pmid:16272807
de Sotomayor MA et al. Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways. 2005 Br. J. Pharmacol. pmid:16231003
Chang Y et al. Mechanisms involved in the antiplatelet activity of ketamine in human platelets. 2004 Nov-Dec J. Biomed. Sci. pmid:15591773
Barrière G et al. PHGPx overexpression induces an increase in COX-2 activity in colon carcinoma cells. 2004 May-Jun Anticancer Res. pmid:15274299
Xu L et al. [Effects of effective component from "qing kai ling" on endothelial cell of microvessel in MCAO rats]. 2004 Zhong Yao Cai pmid:15376390
Perneby C et al. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. 2004 Thromb. Res. pmid:15381386
Hennekens CH et al. Terms and conditions: semantic complexity and aspirin resistance. 2004 Circulation pmid:15381661
Zhao GR et al. [Clinical study on relationship between sluggishness of lung-defensive qi and levels of vasoactive intestinal polypeptide and thromboxane B2]. 2004 Zhong Xi Yi Jie He Xue Bao pmid:15383251
Fiorucci S et al. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. 2004 J. Am. Coll. Cardiol. pmid:15358033
Aikawa K et al. Effects of antioxidants on coronary microvascular spasm induced by epicardial coronary artery endothelial injury in pigs. 2004 Coron. Artery Dis. pmid:15201617
Lorenzoni R et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. 2004 Am. Heart J. pmid:15215815
Korkushko OV et al. [Some mechanisms of the development of endothelial disfunction in aging]. 2004 Fiziol Zh pmid:15174205
Kawano T et al. Acetaldehyde induces histamine release from human airway mast cells to cause bronchoconstriction. 2004 Int. Arch. Allergy Immunol. pmid:15178893
Ishitsuka Y et al. Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs. 2004 J. Pharm. Pharmacol. pmid:15099446
Dinev D and Andonova M The effect of general anesthesia and abdominal surgery upon plasma thromboxane B concentrations in horses. 2004 Vet Anaesth Analg pmid:15053753
Menzies-Gow NJ et al. Endotoxin-induced digital vasoconstriction in horses: associated changes in plasma concentrations of vasoconstrictor mediators. 2004 Equine Vet. J. pmid:15147137
Berrougui H et al. Argan (Argania spinosa) oil lowers blood pressure and improves endothelial dysfunction in spontaneously hypertensive rats. 2004 Br. J. Nutr. pmid:15613254
Fan JG et al. [Dynamic changes of plasma levels of prostacycline and thromboxane A2 and their correlation with the severity of hepatic injury in rats with nonalcoholic fatty liver disease]. 2004 Zhonghua Gan Zang Bing Za Zhi pmid:15623379
Vega-Ostertag M et al. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. 2004 Arthritis Rheum. pmid:15457460
Noverr MC and Huffnagle GB Regulation of Candida albicans morphogenesis by fatty acid metabolites. 2004 Infect. Immun. pmid:15501745
Rocca B et al. Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. 2004 Exp. Hematol. pmid:15504548
Chou DS et al. Low concentration of oxidized low density lipoprotein suppresses platelet reactivity in vitro: an intracellular study. 2004 Lipids pmid:15506238